Zobrazeno 1 - 10
of 660
pro vyhledávání: '"L Czirják"'
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/b0fe9f9cfdc04501ac9e5246ae1210bc
Autor:
J. Blagojevic, S. Bellando-Randone, G. Abignano, J. Avouac, L. Cometi, L. Czirják, C. P. Denton, O. Distler, M. Frerix, S. Guiducci, D. Huscher, V. K. Jaeger, V. Lóránd, B. Maurer, S. Nihtyanova, G. Riemekasten, E. Siegert, I. H. Tarner, S. Vettori, U. A. Walker, Y. Allanore, U. Müller-Ladner, F. Del Galdo, M. Matucci-Cerinic, EUSTAR co-workers
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-6 (2019)
Abstract Background A consensus on digital ulcer (DU) definition in systemic sclerosis (SSc) has been recently reached (Suliman et al., J Scleroderma Relat Disord 2:115-20, 2017), while for their evaluation, classification and categorisation, it is s
Externí odkaz:
https://doaj.org/article/8c4529582f0f4e1a859ac3e248e0660a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A M Hoffmann-Vold, C Brunborg, P Airò, L P Ananyeva, L Czirják, S Guiducci, E Hachulla, M Li, C Mihai, G Riemekasten, P P Sfikakis, G Valentini, O Kowal-Bielecka, Y Allanore, O Distler
Publikováno v:
12.02 - ILD/DPLD of known origin.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A. M. Hoffmann-Vold, C. Brunborg, P. Airò, L. P. Ananyeva, L. Czirják, S. Guiducci, E. Hachulla, M. Li, C. Mihai, G. Riemekasten, P. Sfikakis, G. Valentini, O. Kowal-Bielecka, Y. Allanore, O. Distler
Publikováno v:
Annals of the Rheumatic Diseases. 81:103-104
BackgroundEnrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have been partly successful but have not been tested in a real life cohort.ObjectivesAnalyse the efficacy, represen
Autor:
Silvia Bellando-Randone, Ulrich A. Walker, Marc Frerix, Svetlana I. Nihtyanova, Veronika Lóránd, Marco Matucci-Cerinic, Ingo H. Tarner, Serena Vettori, Veronika K. Jaeger, Ulf Müller-Ladner, Giuseppina Abignano, Jérôme Avouac, G. Riemekasten, Cosimo Bruni, Oliver Distler, L. Czirják, Yannick Allanore, Alberto Moggi-Pignone, F. Del Galdo, Jelena Blagojevic, Laura Cometi, Dörte Huscher, Christopher P. Denton, Britta Maurer, Serena Guiducci, Elise Siegert
Publikováno v:
Clinical Rheumatology. 39:27-36
DeSScipher is the first European multicentre study on management of systemic sclerosis (SSc), and its observational trial 1 (OT1) evaluated the efficacy of different drugs for digital ulcer (DU) prevention and healing. The aim of this study was to as
Autor:
A. M. Hoffmann-Vold, C. Brunborg, P. Airò, L. P. Ananyeva, L. Czirják, S. Guiducci, E. Hachulla, M. Li, C. Mihai, G. Riemekasten, P. Sfikakis, G. Valentini, O. Kowal-Bielecka, Y. Allanore, O. Distler
Publikováno v:
Annals of the Rheumatic Diseases. 81:248-248
BackgroundShort disease duration is a predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease stages are lacking. To individually tailor management of ILD in
Autor:
M. G. Lazzaroni, M. Wilson, E. Hensor, J. H. W. Distler, G. Cuomo, E. Siegert, U. Müller-Ladner, Y. Allanore, M. J. Salvador, B. Anic, U. Walker, L. Czirják, C. Ribi, C. M. Tanaseanu, A. Gabrielli, A. M. Hoffmann-Vold, O. Distler, F. Del Galdo
Publikováno v:
Annals of the Rheumatic Diseases. 81:743.2-744
BackgroundPatient Reported Outcomes (PROs) are central to measure how patients feel and function especially when determining the effect of disease modifying agents. In patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD), d
Autor:
Katalin Böröcz, Péter Németh, É Tuba, Timea Berki, Diána Simon, L. Czirják, Szabina Erdő-Bonyár, Katalin T. Kovacs
Publikováno v:
Clinical and Experimental Immunology
Our goal was to explore immunoserological relations between IgM and IgG isotypes of natural autoantibodies (nAAbs) and pathogen (or vaccine)‐induced or disease‐related antibodies in systemic autoimmune diseases (SAD); systemic sclerosis (SSc), sy